7 results match your criteria: "People's Liberation Army (PLA) Rocket Force Characteristic Medical Center[Affiliation]"
Transl Cancer Res
July 2024
Department of Obstetrics and Gynecology, People's Liberation Army (PLA) Rocket Force Characteristic Medical Center, Beijing, China.
Background: The prognosis of persistent, recurrent or metastatic cervical and endometrial cancer is poor. Anlotinib is a novel multitarget tyrosine kinase inhibitor (TKI). The efficacy and safety of anlotinib in patients with cervical and endometrial cancer need to be evaluated.
View Article and Find Full Text PDFExp Brain Res
January 2024
Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China.
Traumatic brain injury (TBI) leads to disturbed brain discharge rhythm, elevated excitability, anxiety-like behaviors, and decreased learning and memory capabilities. Cognitive dysfunctions severely affect the quality of life and prognosis of TBI patients, requiring effective rehabilitation treatment. Evidence indicates that moderate exercise after brain injury decreases TBI-induced cognitive decline.
View Article and Find Full Text PDFNeural Plast
November 2022
Institute of Neuroscience, Basic Medical College, Kunming Medical University, Kunming, Yunnan 650500, China.
Voltage-gated sodium channel beta 2 (Nav2.2 or Nav2, coded by SCN2B mRNA), a gene involved in maintaining normal physiological functions of the prefrontal cortex and hippocampus, might be associated with prefrontal cortex aging and memory decline. This study investigated the effects of Nav2 in amyloid- 1-42- (A1-42-) induced neural injury model and the potential underlying molecular mechanism.
View Article and Find Full Text PDFFront Oncol
May 2022
Department of Oncology, Fifth Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
The growth of lymphatic vessels (lymphangiogenesis) plays a pivotal role in breast cancer progression and metastasis and the immune response. Vascular endothelial growth factor C (VEGFC) has been demonstrated to accelerate cancer metastasis and modulate the immune system by enhancing lymphangiogenesis. However, it remains largely unclear how transcription factors physically regulate VEGFC expression by interacting with histone-modifying enzymes.
View Article and Find Full Text PDFFront Oncol
September 2021
School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, China.
Background: Although notable therapeutic and prognostic benefits of compound kushen injection (CKI) have been found when it was used alone or in combination with chemotherapy or radiotherapy for triple-negative breast cancer (TNBC) treatment, the effects of CKI on TNBC microenvironment remain largely unclear. This study aims to construct and validate a predictive immunotherapy signature of CKI on TNBC.
Methods: The UPLC-Q-TOF-MS technology was firstly used to investigate major constituents of CKI.
Front Oncol
July 2021
Department of Oncology, General Hospital of Chinese PLA, Beijing, China.
Aims: Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to investigate the efficacy and safety of anlotinib with and without immunotherapy in NSCLC.
Methods: Pathologically confirmed NSCLC patients (stage IIIB-IV) receiving anlotinib between November 2018 and February 2020 were enrolled for retrospective analysis.
Med Sci Monit
January 2021
Department of Anesthesiology, People's Liberation Army (PLA) Rocket Force Characteristic Medical Center, Beijing, China (mainland).
BACKGROUND We aimed to explore the effect of parecoxib sodium on myocardial ischemia-reperfusion (I/R) injury rats and its mechanism. MATERIAL AND METHODS The coronary artery of Sprague-Dawley rats was occluded for 6 h of myocardial ischemia, followed by reperfusion for 30 min (I/R group). Before ischemia, parecoxib sodium (10 mg/kg) was intraperitoneally injected twice a day for 3 consecutive days, followed by reperfusion for 6 h (I/R+Pare group).
View Article and Find Full Text PDF